natgillin/translations-raw huggingface dataset:
The active substance in Mysildecard, sildenafil, belongs to a group of medicines called ‘phosphodiesterase-type-5 (PDE5) inhibitors', which means that it blocks the PDE5 enzyme.
Zdravilna učinkovina v zdravilu Mysildecard, sildenafil, spada v skupino zdravil, imenovanih zaviralci fosfodiesteraze tipa-5 (PDE5), kar pomeni, da zavira encim PDE5.
Mysildecard is a medicine used to treat adults and children from 1 year of age with pulmonary arterial hypertension (PAH, abnormally high blood pressure in the arteries of the lungs).
Zdravilo Mysildecard se uporablja za zdravljenje odraslih in otrok, starejših od enega leta, s pljučno arterijsko hipertenzijo (PAH, nenormalno visokim krvnim tlakom v pljučnih arterijah).
In children aged one to 17, the recommended dose is 20 mg three times a day in those over 20 kg. Higher doses should not be used.
Pri otrocih, starih od 1 do 17 let, je priporočeni odmerek 20 mg trikrat dnevno, če je njihova telesna masa večja od 20 kg. Višji odmerek se ne sme uporabiti.
What are the benefits and risks of Mysildecard?
Kakšne so koristi in tveganja, povezani z zdravilom Mysildecard?
In adults, Mysildecard is taken at a dose of 20 mg three times a day.
Pri odraslih se zdravilo Mysildecard jemlje v odmerku 20 mg trikrat na dan.
This means that Mysildecard is similar to a ‘reference medicine' already authorised in the European Union (EU) called Revatio.
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Revatio.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Mysildecard have been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Mysildecard upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
For more information about treatment with Mysildecard, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Mysildecard preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Other information about Mysildecard
Druge informacije o zdravilu Mysildecard
In children weighing less than 20 kg the maximum recommended
Pri otrocih s telesno maso, manjšo od 20 kg,
For practical information about using Mysildecard, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Mysildecard naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Lower doses of Mysildecard may be needed in patients taking some medicines that affect the way Mysildecard is broken down in the body.
Pri bolnikih, ki jemljejo nekatera zdravila, ki lahko vplivajo na to, kako se zdravilo Mysildecard razgradi v telesu, bodo morda potrebni nižji odmerki tega zdravila.
What is Mysildecard and what is it used for?
Kaj je zdravilo Mysildecard in za kaj se uporablja?
In patients with PAH, sildenafil widens the blood vessels of the lungs, which lowers the blood pressure and improves symptoms.
Sildenafil pri bolnikih s pljučno arterijsko hipertenzijo razširi krvne žile v pljučih, kar zmanjša krvni tlak in olajša simptome.
Mysildecard contains the active substance sildenafil.
Zdravilo Mysildecard vsebuje zdravilno učinkovino sildenafil.
Mysildecard can only be obtained with a prescription and treatment should be started and monitored by a doctor who has experience in the treatment of PAH.
Predpisovanje in izdaja zdravila je le na recept, zdravljenje z njim pa lahko uvede in nadzoruje le zdravnik z izkušnjami z zdravljenjem pljučne arterijske hipertenzije.
It is not intended to provide practical advice on how to use Mysildecard.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Why is Mysildecard approved?
Zakaj je bilo zdravilo Mysildecard odobreno?
How does Mysildecard work?
Kako zdravilo Mysildecard deluje?
How has Mysildecard been studied?
Kako je bilo zdravilo Mysildecard raziskano?
How is Mysildecard used?
Kako se zdravilo Mysildecard uporablja?
Therefore, the CHMP's view was that as for Revatio the benefit of Mysildecard outweighs the identified risks.
Zato je menil, da njegove koristi enako kot pri zdravilu Revatio odtehtajo znana tveganja.
• The risk of opportunistic infections and tuberculosis (TB)
• tveganje za oportunistične okužbe in tuberkulozo (TB)
Do not warm Enbrel in any other way (for example, do not warm it in a microwave or in hot water).
Zdravila Enbrel ne segrevajte na noben drug način (npr. ne segrevajte ga v mikrovalovni pečici ali topli vodi).
Enbrel is recommended for use in patients as defined in section 4.1.
Uporaba zdravila Enbrel je priporočena pri bolnikih, kot je opredeljeno v poglavju 4.1.
Enbrel can be taken with or without food or drink.
Zdravilo Enbrel se lahko uporablja skupaj s hrano ali pijačo ali brez njiju.
TSS Erosions JSN
TSS erozije JSN
• Teaching guide to facilitate training of the patients in the safe use of the pre-filled pen
• učni pripomoček za olajšanje usposabljanja bolnikov o varni uporabi napolnjenega peresnika
Enbrel N=103 to 105*
Enbrel n = 103 do 105*
Long-term experience with Enbrel was generally comparable to the original 48-week study and did not reveal any new safety findings.
Dolgoročne izkušnje z zdravilom Enbrel so v splošnem primerljive s prvotno 48-tedensko študijo in niso pokazale novih dognanj o varnosti.
Date of first authorisation: 03 February 2000 Date of last renewal: 03 February 2010
Datum prve odobritve: 03.02.2000 Datum zadnjega podaljšanja: 03.02.2010
The following list of adverse reactions is based on experience from clinical trials and on postmarketing experience.
Spodnji seznam neželenih učinkov temelji na izkušnjah iz kliničnih preskušanj ter na izkušnjah iz obdobja trženja.
Enbrel should only be used during pregnancy if clearly needed.
Zdravilo Enbrel lahko med nosečnostjo uporabljamo le, če je to nujno potrebno.
Disposing of supplies a.
Odstranjevanje odpadkov a.
Continue to hold the pen firmly against your skin until you hear a second click, or until 10 seconds after the first click (whichever happens first).
Peresnik še naprej čvrsto pritiskajte ob kožo, dokler ne zaslišite drugega klika ali do 10 sekund po prvem kliku (kar se zgodi prej).
It is important that you tell the baby's doctors and other healthcare professionals about the use of Enbrel during pregnancy before the baby receives any vaccine (for more information see section 2, “Vaccinations”).
Pomembno je, da o uporabi zdravila Enbrel med nosečnostjo obvestite dojenčkovega zdravnika in ostale zdravstvene delavce, preden dojenček prejme katerokoli cepivo (za več informacij glejte poglavje 2 “Cepljenja”).
Enbrel is a medicine that is made from two human proteins.
Zdravilo Enbrel je pridobljeno iz dveh človeških beljakovin.
This appearance is normal for Enbrel.
Tak izgled je normalen za zdravilo Enbrel.
The Patient's Alert Card should contain the following key elements for patients treated with Enbrel:
Opozorilna kartica za bolnika mora vsebovati naslednje ključne sestavine za bolnike, ki se zdravijo z zdravilom Enbrel:
• Pull the needle completely out of the vial.
Iglo povsem izvlecite iz viale.
Treatment with Enbrel should continue until remission is achieved, for up to 24 weeks.
Zdravljenje z zdravilom Enbrel je treba nadaljevati, dokler ne dosežemo remisije, vendar največ 24 tednov.
Before starting treatment with Enbrel, all patients must be evaluated for both active and inactive (‘latent') tuberculosis.
Pred začetkom zdravljenja z zdravilom Enbrel je treba vse bolnike pregledati tako glede aktivne kot tudi glede neaktivne ('latentne') tuberkuloze.
Enbrel contains no antibacterial preservative, and therefore, solutions prepared with water for injections should be administered as soon as possible and within 6 hours following reconstitution.
Zdravilo Enbrel ne vsebuje antibakterijskih konzervansov, zato je treba raztopino, pripravljeno z vodo za injekcije, injicirati čimprej oziroma najkasneje v 6 urah po rekonstituciji.
Enbrel treatment resulted in improvement in physical function during the double-blind period, and this benefit was maintained during the longer-term exposure of up to 2 years.
Zdravljenje z zdravilom Enbrel je povzročilo izboljšanje telesne funkcije v dvojno slepem obdobju, ta koristni učinek pa se je ohranjal med dolgotrajnejšo izpostavljenostjo, ki je trajala do 2 leti.
• Your doctor will also give you a Patient Alert Card, which contains important safety information that you need to be aware of before and during treatment with Enbrel.
Zdravnik vam bo izročil tudi opozorilno kartico za bolnika, ki vsebuje pomembne podatke o varnosti, s katerimi morate biti seznanjeni pred zdravljenjem z zdravilom Enbrel in med zdravljenjem z njim.
Frequency Not Known (C an n ot be Estimated from Available Data)
Neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov)
In long-term (up to 34 months) open-label studies where Enbrel was given without interruption, clinical responses were sustained and safety was comparable to shorter-term studies.
V dolgoročnih (do 34 mesecev) odprtih študijah, v katerih so dajali zdravilo Enbrel brez prekinitev, so bili klinični odzivi trajni, varnost pa je bila primerljiva s tisto v krajših študijah.
Administration of live vaccines to infants for 16 weeks after the mother's last dose of Enbrel is generally not recommended.
Uporaba živih cepiv v prvih 16 tednih po tem, ko so matere dojenčkov prejele zadnji odmerek zdravila Enbrel, pri dojenčkih običajno ni priporočljiva.
Women of childbearing potential should consider the use of appropriate contraception to avoid becoming pregnant during Enbrel therapy and for three weeks after discontinuation of therapy.
Ženske v rodni dobi morajo razmisliti o uporabi ustrezne kontracepcije za preprečitev nosečnosti med zdravljenjem z zdravilom Enbrel in še tri tedne po prenehanju zdravljenja.
Prior to launch in each Member State, the MAH shall agree the final educational material with the competent authority in that Member State comprising of information provided to all healthcare professionals expected to prescribe the product on the correct and safe use of the pre-filled pen and a Patient Alert Card which is to be given to patients using Enbrel.
Imetnik dovoljenja za promet z zdravilom se mora pred pričetkom trženja napolnjenega peresnika v vsaki državi članici s pristojnim organom v tej državi dogovoriti glede končnega izobraževalnega gradiva, sestavljenega iz informacij za vse zdravstvene delavce, za katere se pričakuje, da bodo predpisovali to zdravilo, glede pravilne in varne uporabe napolnjenega peresnika, ter opozorilne kartice za bolnika, ki jo morajo izročiti bolnikom, ki se zdravijo z zdravilom Enbrel.
The use of Enbrel in combination with other systemic therapies or phototherapy for the treatment of psoriasis has not been studied.
Uporaba zdravila Enbrel v kombinaciji z drugimi sistemskimi zdravljenji ali fototerapijo za zdravljenje psoriaze ni raziskana.
Two large clinical trials evaluating the use of Enbrel in the treatment of CHF were terminated early due to lack of efficacy.
Dve veliki klinični preskušanji za ovrednotenje uporabe zdravila Enbrel pri zdravljenju KSP sta bili predčasno prekinjeni zaradi slabe učinkovitosti zdravila.
Treatment with Enbrel 25 mg resulted in substantial improvement at 12 months, with about 44% of patients achieving a normal HAQ score (less than 0.5).
Z zdravljenjem s 25 mg zdravila Enbrel so dosegli bistveno izboljšanje pri 12 mesecih - približno 44 % bolnikov je doseglo normalen rezultat HAQ (manj kot 0,5).
Some children and teenage patients who have received Enbrel or other medicines that work the same way as Enbrel have developed cancers, including unusual types, which sometimes resulted in death.
Pri nekaterih otrocih in mladostnikih, ki so prejemali zdravilo Enbrel ali druga podobna zdravila z enakim načinom delovanja kot zdravilo Enbrel, se je razvil rak, vključno z neobičajnimi oblikami, ki se je včasih končal s smrtjo.
The known side effects of Enbrel include the following in groups of decreasing frequency:
Znani neželeni učinki zdravila Enbrel so v nadaljevanju navedeni v skupinah po padajoči pogostnosti:
What you need to know before you use Enbrel
Kaj morate vedeti, preden boste uporabili zdravilo Enbrel
The effect of Enbrel on radiographic progression was maintained in patients who continued on treatment during the second year.
Učinek zdravila Enbrel na radiografsko napredovanje bolezni se je ohranjal pri bolnikih, ki so nadaljevali zdravljenje še drugo leto.
Enbrel + Methotrexate
Enbrel + metotreksat
Because immunoglobulins, in common with many medicinal products, can be excreted in human milk, a decision must be made whether to discontinue breast-feeding or to discontinue Enbrel therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Ker se imunoglobulini, tako kot mnoga druga zdravila, lahko izločajo v mleko pri človeku, se je treba odločiti, ali bo med zdravljenjem z zdravilom Enbrel bolnica prenehala dojiti ali pa bo med dojenjem prekinila zdravljenje s tem zdravilom, pri čemer je treba upoštevati tako korist dojenja za otroka kot korist zdravljenja za mater.
What Enbrel is and what it is used for What you need to know before you use Enbrel How to use Enbrel
Kaj je zdravilo Enbrel in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Enbrel Kako uporabljati zdravilo Enbrel
To help you remember, it may be helpful to write in a diary which day(s) of the week Enbrel should be used.
Da si boste lažje zapomnili, vam bo morda pomagalo, če si v koledarju zabeležite dan (dneve) v tednu, ko morate uporabiti zdravilo Enbrel.
Your doctor will determine the correct dose for the child and will prescribe an appropriate strength of Enbrel (10 mg, 25 mg or 50 mg).
Natančen odmerek za otroka bo določil zdravnik in predpisal ustrezno jakost zdravila Enbrel (10 mg, 25 mg ali 50 mg).
In addition, one study found more birth defects when the mother had received Enbrel in pregnancy, compared with mothers who had not received Enbrel or other similar medicines (TNF-antagonists), but there was no particular kind of birth defect reported.
Poleg tega so v eni študiji ugotovili več prirojenih napak, kadar je mati med nosečnostjo prejemala zdravilo Enbrel, v primerjavi z materami, ki niso prejemale zdravila Enbrel ali drugih podobnih zdravil (antagonistov TNF), vendar niso poročali o nobeni določeni vrsti prirojene okvare.
In this situation, the benefit/risk balance of Enbrel therapy should be very carefully considered.
V takem primeru je treba zelo skrbno pretehtati razmerje med koristmi in tveganji zdravljenja z zdravilom Enbrel.
Enbrel works by reducing the inflammation associated with certain diseases.
Deluje tako, da zmanjšuje vnetje, ki spremlja določene bolezni.
It is recommended that you record the date that Enbrel is removed from the refrigerator and the date after which Enbrel should be discarded (no more than 4 weeks following the removal from the refrigerator).
Priporočljivo si je zabeležiti datum odvzema zdravila Enbrel iz hladilnika in datum, po katerem je treba zdravilo Enbrel zavreči (do 4 tedne po odvzemu iz hladilnika).
If the window is not completely purple, contact your nurse or pharmacist for assistance, since the pen may not have injected the Enbrel solution completely.
Če okence ni povsem vijolično, za pomoč prosite medicinsko sestro ali farmacevta, saj peresnik raztopine zdravila Enbrel morda ni injiciral v celoti.
What Enbrel is and what it is used for
Kaj je zdravilo Enbrel in za kaj ga uporabljamo
For patients with multiple symmetrical painful or swollen joints (e.g., hands, wrists and feet), Enbrel can slow down the structural damage to those joints caused by the disease.
Pri bolnikih z več simetrično prizadetimi bolečimi ali oteklimi sklepi (npr. dlanmi, zapestji ali stopali) lahko zdravilo Enbrel upočasni razvoj strukturnih okvar teh sklepov, ki jih povzroča bolezen.
If you received Enbrel during pregnancy, your baby may have a higher risk of getting an infection.
Če ste med nosečnostjo prejeli zdravilo Enbrel, lahko pri vašem dojenčku obstaja povečano tveganje za razvoj okužbe.
Serious infections occurred in 6.3% of rheumatoid arthritis patients treated with Enbrel for up to 48 months.
Resne okužbe so se pojavile pri 6,3 % bolnikov z revmatoidnim artritisom, ki so prejemali zdravilo Enbrel do 48 mesecev.
Do not use the solution if it is discoloured, cloudy, or if particles other than those described above are present.
Raztopine ne uporabljajte, če je drugačne barve, motna ali če so prisotni delci, ki ne ustrezajo opisu zgoraj.
If you have used more Enbrel than you should (either by injecting too much on a single occasion or by using it too frequently), talk to a doctor or pharmacist immediately.
Če ste uporabili večji odmerek zdravila Enbrel, kot bi smeli (bodisi ste ga naenkrat injicirali preveč bodisi prepogosto), se nemudoma posvetujte z zdravnikom ali farmacevtom.
After discontinuation of Enbrel, symptoms of arthritis generally returned within a month.
Po prekinitvi zdravljenja z zdravilom Enbrel so se simptomi artritisa največkrat ponovno pojavili že v enem mesecu.
The impact of long-term treatment with Enbrel on the development of autoimmune diseases is unknown.
Vpliv dolgotrajnega zdravljenja z zdravilom Enbrel na razvoj avtoimunskih bolezni ni znan.
On the basis of the scientific conclusions for etanercept (except for biosimilars) the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing etanercept (except for biosimilars) is unchanged subject to the proposed changes to the product information
Na podlagi znanstvenih zaključkov za etanercept (razen podobnih bioloških zdravil) odbor CHMP meni, da je razmerje med koristjo in tveganjem zdravil(-a), ki vsebuje(-jo) etanercept (razen podobnih bioloških zdravil), nespremenjeno ob upoštevanju predlaganih sprememb v informacijah o zdravilu.
Enbrel treatment may increase mortality in patients with established sepsis.
Zdravljenje z zdravilom Enbrel lahko zveča smrtnost pri bolnikih z dokazano sepso.
The safety and efficacy profiles of the two Enbrel treatment regimens were comparable at week 8 in their effect on signs and symptoms of RA; data at week 16 did not show comparability (non-inferiority) between the two regimens.
Profil varnosti in učinkovitosti obeh shem zdravljenja z zdravilom Enbrel je bil po 8 tednih primerljiv glede učinka na znake in simptome revmatoidnega artritisa; podatki po 16 tednih niso pokazali primerljivosti (neinferiornosti) med obema shemama.
If you feel that the effect of Enbrel is too strong or too weak, talk to your doctor or pharmacist.
Če menite, da je učinek zdravila Enbrel premočan ali prešibak, se posvetujte z zdravnikom ali farmacevtom.
If you use more Enbrel than you should
Če ste uporabili večji odmerek zdravila Enbrel, kot bi smeli
Do NOT use Enbrel if all the powder in the vial is not dissolved within 10 minutes.
NE uporabite zdravila Enbrel, če se ves prašek v viali ni raztopil v 10 minutah.
If inactive (‘latent') tuberculosis is diagnosed, treatment for latent tuberculosis must be started with anti-tuberculosis therapy before the initiation of Enbrel, and in accordance with local recommendations.
Če se ugotovi neaktivna ('latentna') tuberkuloza, je treba pred uvedbo zdravila Enbrel in v skladu z nacionalnimi priporočili začeti zdravljenje latentne tuberkuloze s tuberkulostatiki.
Enbrel did not induce lethality or notable signs of toxicity in mice or rats following a single subcutaneous dose of 2000 mg/kg or a single intravenous dose of 1000 mg/kg.
Zdravilo Enbrel ni povzročilo smrtnosti ali pomembne toksičnosti pri miših ali podganah po enkratnem subkutanem odmerku 2.000 mg/kg ali enkratnem intravenskem odmerku 1.000 mg/kg.
Patients who develop a new infection while undergoing treatment with Enbrel should be monitored closely.
Bolnike, pri katerih se med zdravljenjem z zdravilom Enbrel pojavi nova okužba, je treba skrbno spremljati.
Although not conclusive, data from one of these trials suggest a possible tendency toward worsening CHF in those patients assigned to Enbrel treatment.
Izsledki sicer še niso dokončni, vendar podatki iz enega od teh preskušanj kažejo na morebitno tendenco k poslabšanju KSP pri bolnikih, zdravljenih s tem zdravilom.
There have been reports of worsening of hepatitis C in patients receiving Enbrel.
Poročali so o poslabšanju hepatitisa C pri bolnikih, ki so prejemali zdravilo Enbrel.
• Alcohol abuse: Enbrel should not be used for the treatment of hepatitis related to alcohol abuse.
Zloraba alkohola: Zdravila Enbrel ne smete uporabljati za zdravljenje hepatitisa, povezanega z zlorabo alkohola.
Within the organ system classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare
Znotraj organskih sistemov so neželeni učinki navedeni po pogostnosti (število bolnikov, pri katerih se pričakuje pojav učinka), z uporabo naslednjih kategorij: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000); neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Enbrel is also prescribed for the treatment of the following diseases in children and adolescents
Zdravilo Enbrel se predpisuje tudi za zdravljenje naslednjih bolezni pri otrocih in mladostnikih:
Patients should be evaluated for infections before, during, and after treatment with Enbrel, taking into consideration that the mean elimination half-life of etanercept is approximately 70 hours (range 7 to 300 hours).
Pred zdravljenjem z zdravilom Enbrel, med njim in po njem je treba bolnike pregledati glede okužb in pri tem upoštevati, da je povprečni razpolovni čas izločanja etanercepta iz telesa približno 70 ur (razpon 7 do 300 ur).
Children and adults taking Enbrel may have an increased risk of developing lymphoma or another cancer.
Pri otrocih in odraslih, ki prejemajo zdravilo Enbrel, je morda tveganje za nastanek limfoma ali druge oblike raka večje.
Other medicines and Enbrel
Druga zdravila in zdravilo Enbrel
PsARC Month 3
PsARC 3. mesec b
• Push the plunger in VERY SLOWLY until all the water for injections is in the vial.
ZELO POČASI potiskajte bat v brizgo, dokler ne iztisnete vse vode za injekcije v vialo.
Compared to placebo, treatment with Enbrel resulted in statistically significant improvement in the ASAS 40, ASAS 20 and ASAS 5/6.
Zdravljenje z zdravilom Enbrel je v primerjavi s placebom povzročilo statistično pomembno izboljšanje ASAS 40, ASAS 20 in ASAS 5/6.
The 10 mg Enbrel dose had consistently less effect on structural damage than the 25 mg dose.
10 mg odmerek zdravila Enbrel je imel ves čas manjši učinek na strukturno poškodbo sklepov kot 25 mg odmerek.
If active tuberculosis is diagnosed, Enbrel therapy must not be initiated.
Če je postavljena diagnoza aktivne tuberkuloze, se zdravljenja z zdravilom Enbrel ne sme uvesti.
Enbrel was significantly better than placebo in all measures of disease activity (p < 0.001), and responses were similar with and without concomitant methotrexate therapy.
Zdravilo Enbrel je bilo pomembno boljše kot placebo po vseh kriterijih aktivnosti bolezni (p < 0,001) in odzivi so bili podobni, ne glede na sočasno zdravljenje z metotreksatom.
In patients who develop HBV infection, Enbrel should be stopped and effective anti-viral therapy with appropriate supportive treatment should be initiated.
Pri bolnikih, pri katerih se razvije okužba s HBV, je treba zdravljenje z zdravilom Enbrel prekiniti in uvesti učinkovito protivirusno ter ustrezno podporno zdravljenje.
After preparing the Enbrel solution, immediate use is recommended (up to a maximum of 6 hours).
Po pripravi naj se raztopina zdravila Enbrel po možnosti uporabi takoj (v največ 6 urah).
Adding water for injections e.
Dodajanje vode za injekcije e.